MIT researchers built LUCID, a flexible implant as thin as cardstock that releases drugs in the brain and uses 24 tiny ultrasound transducers to spread them farther. It has been tested in a tissue model and in mice.
In a University of Calgary trial, 82% of 24 glioblastoma patients given high-dose niacin with standard treatment had no cancer progression after six months, against about 54% in earlier studies. The trial is small and has no control group.